Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sherene Loi

Showing results (171-180 of 325) with videos related to

Pageof 33
Sort By:
The Oncologist|June 28, 2017
Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 ResultsSibylle Loibl, Nicholas C Turner, Jungsil Ro, et al.
Plos One|August 21, 2008
Identification of functional networks of estrogen- and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancerElizabeth A Musgrove, C Marcelo Sergio, Sherene Loi, et al.
Breast Cancer Research : BCR|August 20, 2020
Clinical implications of prospective genomic profiling of metastatic breast cancer patientsCourtney T van Geelen, Peter Savas, Zhi Ling Teo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2013
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98Sherene Loi, Nicolas Sirtaine, Fanny Piette, et al.
JCO Precision Oncology|January 18, 2024
Prediction of Benefit From Adjuvant Pertuzumab by 80-Gene Signature in the APHINITY (BIG 4-11) TrialIan E Krop, Lorenza Mittempergher, Joseph N Paulson, et al.
The Lancet. Oncology|October 1, 2020
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trialLeisha A Emens, Francisco J Esteva, Mark Beresford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2007
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic gradeSherene Loi, Benjamin Haibe-Kains, Christine Desmedt, et al.
International Journal of Cancer|January 7, 2020
Reactive stroma and trastuzumab resistance in HER2-positive early breast cancerAmir Sonnenblick, Mali Salmon-Divon, Roberto Salgado, et al.
Contemporary Clinical Trials Communications|January 25, 2021
A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocolDavid Pryor, Mathias Bressel, Nathan Lawrentschuk, et al.
Cancer Research|January 14, 2017
A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T CellsSherly Mardiana, Liza B John, Melissa A Henderson, et al.
Pageof 33

Showing results (171-180 of 325) with videos related to

Sort By:
Pageof 33
The Oncologist|June 28, 2017
Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 ResultsSibylle Loibl, Nicholas C Turner, Jungsil Ro, et al.
Plos One|August 21, 2008
Identification of functional networks of estrogen- and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancerElizabeth A Musgrove, C Marcelo Sergio, Sherene Loi, et al.
Breast Cancer Research : BCR|August 20, 2020
Clinical implications of prospective genomic profiling of metastatic breast cancer patientsCourtney T van Geelen, Peter Savas, Zhi Ling Teo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2013
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98Sherene Loi, Nicolas Sirtaine, Fanny Piette, et al.
JCO Precision Oncology|January 18, 2024
Prediction of Benefit From Adjuvant Pertuzumab by 80-Gene Signature in the APHINITY (BIG 4-11) TrialIan E Krop, Lorenza Mittempergher, Joseph N Paulson, et al.
The Lancet. Oncology|October 1, 2020
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trialLeisha A Emens, Francisco J Esteva, Mark Beresford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2007
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic gradeSherene Loi, Benjamin Haibe-Kains, Christine Desmedt, et al.
International Journal of Cancer|January 7, 2020
Reactive stroma and trastuzumab resistance in HER2-positive early breast cancerAmir Sonnenblick, Mali Salmon-Divon, Roberto Salgado, et al.
Contemporary Clinical Trials Communications|January 25, 2021
A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocolDavid Pryor, Mathias Bressel, Nathan Lawrentschuk, et al.
Cancer Research|January 14, 2017
A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T CellsSherly Mardiana, Liza B John, Melissa A Henderson, et al.
Pageof 33